
Ekso Bionics Holdings Inc EKSO.OQ EKSO.O is expected to show a rise in quarterly revenue when it reports results on March 3 for the period ending December 31 2024
The San Rafael California California-based company is expected to report a 4.2% increase in revenue to $5.053 million from $4.85 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Ekso Bionics Holdings Inc is for a loss of 8 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Ekso Bionics Holdings Inc is $5.50, above its last closing price of $0.52.
This summary was machine generated February 28 at 21:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)